Trading update: Unaudited Revenues up 366% to £1m Integumen’s subsidiary Labskin today announces that it has signed a Memorandum of [...]

Continued strong growth towards profitability Integumen (LSE: SKIN), the vertically integrated skin product test services company, today announces its interim [...]

We have entered a new era where an Artificially Intelligent (AI) Laboratory today is becoming more science, than science fiction. [...]

Labskin breakthrough clones 16 human skin swabs into 54 living microbiome test subjects Labskin scientists cloned 16 swabs of skin [...]

Integumen today announces the expansion of its wound care division, LifeScienceHub Ltd (Wound pHase), as it extends its license technology [...]

Strong H1 2019 Revenue Growth Continues Trading Update The positive results of major restructuring in H2 2018 has delivered accelerated [...]

Integumen (LSE: SKIN), today announces its final results for the year ended 31 December 2018. Highlights Total revenue £501k (including discontinued [...]

Integumen today announces that Labskin AI, the virtual laboratory platform, has entered into testing agreements with three new clients – [...]

Trading update – board changes Trading Update Integumen announces the resignation of Tony Richardson as Chairman and a director of [...]

Launch of Labskin human skin clone tests for Medical Device and Clinical Research trials Integumen today announces the roll-out of [...]

Fionán Murray has joined Integumen as Group Sales Director, and as a Director of the Company with a focus on [...]

Turner Pope Investor Evening Integumen is pleased to announce that Gerry Brandon, the Company’s CEO, will be presenting at an [...]

Integumen today announces the completion of development and launch of a new dandruff test on its animal-free Labskin test platform. [...]

Proposed Placing and Subscription of £2.518m Acquisition, Placing & Subscription Integumen plc, (AIM: SKIN, is pleased to announce that the [...]

Labskin secures digital automation and integration through £400,000 Cellulac – Integumen deferred loan agreement Integumen plc (AIM: SKIN), is pleased [...]

Labskin CBD tests show greater than 99% reduction in bacterial growth on human skin Integumen plc (AIM: SKIN) is pleased [...]

Restructuring is Accelerating Growth into 2019 Trading Update The Company is pleased to announce the positive results of major restructuring [...]

Divestment of TSPro GmbH to remove c€1.34m (£1.19m) of short and long term liabilities from Integumen Today the Company announces [...]

Labskin-On-A-Chip to monitor real-time skin related diseases and Labskin-AI data analysis to predict the best course of treatment Integumen is [...]

Major Restructuring Causing Increased Growth The Company is pleased to announce the increased growth in product sales and contract test [...]

First laboratory-grown human-skin test service, to use artificial intelligence, to provide clinical validation for cosmetic, personal hygiene and skin care [...]

Chairman’s Statement Introduction Since Integumen’s  admission to trading on AIM in April 2017, the integration of multiple isolated and diverse [...]

Integumen (LSE: SKIN), the non-animal-testing, skin care and cosmetic businesses developing and commercialising technologies and products for consumer use today [...]